Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera - European Medical Journal

Follow up of the phase 3 RESPONSE trial of ruxolitinib in polycythemia vera

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris Diderot Paris, France, discusses follow-up data of the RESPONSE trial, which is a multicentre, open-label phase 3 study evaluating the efficacy and safety of ruxolitinib compared with best available therapy in patients with polycythemia vera resistant to or intolerant of hydroxyurea.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>